Omeros (OMER) Competitors

Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.

Do analysts recommend ASMB or OMER?

Assembly Biosciences currently has a consensus price target of $33.00, indicating a potential upside of 92.98%. Omeros has a consensus price target of $18.00, indicating a potential upside of 407.04%. Given Omeros' stronger consensus rating and higher possible upside, analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Omeros	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.83

Is ASMB or OMER more profitable?

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -144.05%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-144.05%	-121.46%	-34.56%
Omeros	N/A	N/A	-49.92%

Does the media refer more to ASMB or OMER?

In the previous week, Omeros had 15 more articles in the media than Assembly Biosciences. MarketBeat recorded 23 mentions for Omeros and 8 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.83 beat Assembly Biosciences' score of 0.16 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Omeros	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ASMB or OMER?

Omeros received 508 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.61% of users gave Omeros an outperform vote while only 58.65% of users gave Assembly Biosciences an outperform vote.

Company	Underperform	Outperform
Assembly Biosciences	Outperform Votes 244 58.65%	Underperform Votes 172 41.35%
Omeros	Outperform Votes 752 70.61%	Underperform Votes 313 29.39%

Do institutionals and insiders believe in ASMB or OMER?

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by insiders. Comparatively, 12.3% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has higher earnings and valuation, ASMB or OMER?

Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$32.15M	4.06	-$61.23M	-$6.23	-2.74
Omeros	N/A	N/A	-$117.81M	-$2.65	-1.34

Which has more risk & volatility, ASMB or OMER?

Assembly Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.

Summary

Omeros beats Assembly Biosciences on 15 of the 18 factors compared between the two stocks.